A B S T R A C T The rate of clotting and the rate of development and degree of turbidity after addition of thrombin to plasma or purified fibrinogen from a patient with fibrinogen Baltimore was delayed when compared with normal, especially in the presence of low concentrations of thrombin. Optimal coagulation and development of translucent, rather than opaque, clots occurred at a lower pH with the abnormal fibrinogen than with normal. Development of turbidity during clotting of the abnormal plasma or fibrinogen was less than normal at each pH tested, but was maximal in both at approximately pH 6.4. The physical quality of clots formed from fibrinogen Baltimore was abnormal, as demonstrated by a decreased amplitude on thromboelastography. The morphologic appearance of fibrin strands formed from fibrinogen Baltimore by thrombin at pH 7.4 was abnormal when examined by phase contrast or electron microscopy, but those formed by thrombin at pH 6.4 or by thrombin and calcium chloride were similar to, though less compact, than normal fibrin. The periodicity of fibrin formed from fibrinogen Baltimore was similar to normal and was 231-233 A.
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A study of the release of the fibrinopeptides from the patient's fibrinogen and its chromatographic subfractions verified the existence of both a normally behaving and a defective form of fibrinogen in the patient's plasma. The defective form differed from normal in three functionally different ways: (a) the rate of release of fibrinopeptides A and AP was slower than normal; (b) no 
INTRODUCTION
In 1958 Imperato and Dettori (1) described a functionally defective fibrinogen in the plasma of a young girl with a congenital bleeding disorder, but no other affected individuals were encountered in a study of her family. Abnormal fibrinogens occurring in successive generations have been recognized in at least seven families (2) (3) (4) (5) (6) (7) (8) . Abnormal fibrinogens inherited as dominants have been demonstrated (9, 10) in two additional families originally reported as having congenital hypofibrinogenemia (11) and factor XIII deficiency (12) . The precise molecular defects of these abnormal fibrinogens remain unknown, although an amino acid substitution (arginine to serine) in the N-terminal portion of the a-(A)-chain (13) and a decreased content of carbohydrate (7) have been reported in one. A comparative study (9) of six of the abnormal fibrinogens (2-4, 6, 7, 11) suggested that at least five (2-4, 6, 7) are distinct. A nomenclature similar to that used to designate the abnormal hemoglobins has been suggested (3) for the tentative identification of inherited abnormal fibrinogens.
We have reported (3, 14) preliminary studies of an abnormal fibrinogen which has been designated fibrinogen Baltimore (3) . These studies were performed on the blood of a young woman with a history of recurrent thrombosis, pulmonary emboli, and mild bleeding. Bovine thrombin' (1000 NIH U per ml) was dissolved in barbital buffer, pH 7.4, stored at -200C, thawed immediately before use, and diluted to the desired concentration with barbital buffer. Activity of the diluted thrombin was tested using normal plasma or purified fibrinogen during the course of each experiment. The rate of clotting of plasma or fibrinogen after addition of thrombin (i.e. thrombin clotting time) was determined at 37'C using a wire loop to determine the end point (16) . The first appearance of fibrin threads on the wire loop was taken as the end point.
Thrombin used for studies on fibrinopeptide release consisted of both bovine and human' material. Fibrinogen was prepared from citrated or ACD plasma obtained from the patient or individual, normal subjects. Fraction I-2 was prepared by the method of Blombdck and Blombdck (17) and processed further (18) to remove coldinsoluble protein. Clottability of the preparations of purified fibrinogen was at least 95%, as determined by the spectrophotometric procedure of Laki (18) . Purified fibrinogen was measured by the method of Ratnoff and Menzie (19) modified to allow maximal polymerization by adjusting the pH to 6.4 with 0.15 M phosphate buffer and incubation for at least 12 hr at 4VC.
Aggregation of preformed, dissolved fibrin was achieved by a shift of pH from 5.4 to neutrality, as originally suggested by Mommaerts (20) . In some studies coagulation of preformed fibrin was evaluated by a modification of this 'G. E. Silicone SC-87 dri-film. 2Abbreviations used in this paper: AP, phosphorylated peptide; ACD, acid citrate dextrose; TCA, tricholoracetic 'Fibrindex, Ortho Diagnostics, Raritan, N. J. method, as described by Forman, Ratnoff, and Boyer (6).
In these studies, 0.5 ml of plasma was acidified with 1 ml of Michaelis buffer to obtain a final pH of 5.4. Thrombin (100 NIH U) was added and the mixtures were incubated at 370C for various intervals. Portions (0.1 ml) of the mixture then were added to buffered hirudin to inhibit the enzymatic action of thrombin and neutralize the pH.
Changes in turbidity during coagulation of plasma or purified fibrinogen after addition of thrombin were measured at room temperature in a Beckman DBG spectrophotometer at 350 nm and recorded graphically. Mixing of the samples in the cuvette and closing of the shutter was achieved within 3-5 sec. The corresponding part of curves on graphs was extrapolated towards zero or, if initial turbidity was recorded, following the base line.
Fibrin was prepared for electron microscopy directly on carbon-coated collodion membranes, using a modification (21) of the method of Kay and Cuddigan (22) .
The rate of release of fibrinopeptides was studied by treating samples (1 ml containing 1.8 mg fibrinogen) with thrombin (20 IAI containing 0.024 U) at 250C and then stopping the reaction after alloted times by precipitating protein with 5% trichloroacetic acid (TCA). The supernatant fluids were processed (23) to remove the TCA and salt, and then subjected to paper electrophoresis to separate the fibrinopeptides. Electrophoresis was performed as described previously (23) , except that the buffer consisted of 0.045 M potassium orthoborate at pH 8.6. Quantitation was based on arginine content as determined with a modification (24) of Sakaguchi's reaction. Densitometry was performed with a Joyce Loebl (Gateshead, England) "Roboscan" fitted with a 500 nm wave-length filter.
RESULTS
The rate of clotting of the patient's plasma or purified fibrinogen after addition of thrombin (i.e. thrombin clotting time) was delayed when compared to normal plasma or fibrinogen in all of the test systems employed. Differences in the rates of clotting of the patient's and normal plasma by thrombin were accentuated by de- plasma by thrombin was delayed as compared with normal plasma, even in the presence of calcium chloride ( Fig. 1) . Addition of calcium chloride to plasma preincubated with thrombin accelerated the rate of clotting of the patient's and normal plasma, but the results were dependent upon the concentration of thrombin employed ( Fig. 1 ). Coagulation of plasma or fibrinogen also was observed by measurement of increase in turbidity which reflects formation and aggregation of fibrin under appropriate conditions. The rate of development and degree of turbidity after addition of thrombin to the patient's plasma or purified fibrinogen was markedly impaired as compared with normal ( Fig. 2) . Addition of calcium chloride enhanced, but did not completely normalize, the development of turbidity of the patient's fibrin in this test system.
Optimal coagulation of the patient's plasma occurred over a narrow range of pH around 6.3, whereas normal plasma clotted optimally over a wider range of pH (Fig. 3 ). Under these conditions, solid though translucent clots formed from normal plasma at pH 8.5 and at lower pH values the clots were opaque. The patient's plasma did not clot at pH values above 7.9 and translucent clots were noted at pH 7.2. The rate of development and degree of turbidity during clotting of the patient's plasma or purified fibrinogen also occurred over a narrower range of pH and was less than that of normal at each pH tested. Maximum turbidity was reached, both in normal and patient's plasma, between pH 6.3 and 6.5 (Fig. 4) .
Coagulation of preformed, unpolymerized fibrin derived from normal or patient's fibrinogen was measured by the method of Forman et al. (6) . Normal plasma that was preincubated with thrombin for 2 min clotted within 30 sec after neutralization and after preincubation for 16 min, within 22 sec. No visible clot formed after neutralization of the patient's plasma, which had been preincubated with thrombin for as long as 60 min, unless calcium chloride (0.1 ml, 0.05 M) was added at pH 7.4.
The rate of clotting of normal plasma by thrombin was not significantly inhibited by the patient's plasma (Fig. 5) . The thrombin clotting time of normal plasma was prolonged by addition of greater than 25% by volume of the patient's plasma, but the degree of prolongation was less than that produced by addition of comparable amounts of buffer at each of the concentrations tested (Fig. 5) .
The physical quality of clots formed was evaluated by thromboelastography (Fig. 6 ). The amplitude obtained after recalcification of the patient's plasma, with b ---a..ISiuEIEE~hE~inE Morphologic studies by light and phase contrast microscopy of sections of clots formed after addition of thrombin alone to the patient's plasma revealed an irregular, fragmented appearance of the fibrin strands in contrast to the more regular, granular appearance of the normal (Fig. 7) . The fibrin strands, formed by addition of thrombin and calcium chloride to the patient's and normal plasma, appeared relatively coarse and similar to each other (Fig. 7) . Observations by electron microscopy demonstrated that the fibrin strands which formed from the patient's plasma after addition of thrombin alone at pH 7.4 appeared thinner and more fragmented than normal fibrin strands (Fig. 8) . In other studies, the average diameter of the patient's and normal fibrin were similar and the abnormal fibrin appeared as a regular network after addition of either thrombin at pH 6.4 or thrombin and calcium chloride. However, at higher magnification, the fibrin strands derived from the abnormal fibrinogen appeared less compact than normal fibrin. The periodicity of the patient's fibrin and normal fibrin were similar and averaged 231-233 A for both (Fig. 9) .
Proteolytic attack of thrombin upon the patient's fibrinogen was demonstrated by the release of TCAsoluble peptide fragments. The peptides had the same electrophoretic mobilities as the fibrinopeptides from normal fibrinogen (Fig. 10) . The rate of release of fibrinopeptide A and its congeners AY and AP (25) Another indication of a difference in rate of fibrinopeptide release was the observation that the release of fibrinopeptide AP from the patient's fibrinogen consistently lagged behind fibrinopeptide A (Fig. 10, midpatterns) . No such difference in release of fibrinopeptides A and AP from normal fibrinogen has been observed in our laboratory (Fig. 10, lower patterns) . These observations suggested that there were two components in the patient's fibrinogen-one that was reacting with A B 0.1k C FIGURE 9 Periodicity of fibrin strands derived from normal and patient's plasma. Films of plasma were immersed in thrombin (10.0 NIH U per ml) in barbital buffer at pH 7.4 or 6.4 and incubated at room temperature for 2 min before fixation. Original magnification X 160,000. A, Fibrin from normal plasma clotted at pH 7.4; B, Fibrin from normal plasma clotted at pH 6.4; C, Fibrin from the patient's plasma clotted at pH 6.4. thrombin at a normal rate and giving little fibrinopeptide AP, and a second that was reacting at a slow rate and giving the bulk of the fibrinopeptide AP.
Previous work (26) had shown that a defective form of fibrinogen was chromatographically separable from a normally behaving form of fibrinogen occurring in the patient's plasma. A separation of these two forms was made and their fibrinopeptide contents determined. As expected (26), the defective component was eluted in a boundary just behind the normally behaving component. The defective component gave no clot when treated with thrombin in 0.3 M NaCl, as in Fig. 11 , while the normally behaving component clotted in the expected (26) way. Electrophoretic analysis of fibrinopeptides (Fig. 10, upper patterns) from the components verified that the defective component had reacted with thrombin. Aside from its poor clottability, the defective component was found to differ from the normal in a second respect, in that it had a fairly high proportion of phosphorylated, relative to nonphosphorylated, fibrinopeptide A (Fig. 10, upper patterns) . The normally behaving component contained virtually no phosphorylated fibrinopeptide. Total yields of fibrinopeptide were the same for both subfractions of the fibrinogen, being of the order of 1 'mole of both the A group and the B fibrinopeptides per 0.2 g equivalents protein.
Enough material was available to make a single measurement of the relative rates of release of fibrinopeptides A and AP from the defective chromatographed fibrinogen. This was done by stopping the reaction after only 45 min incubation which, according to conditions of reaction, corresponded to the time at which twothirds of fibrinopeptide A would be released from normal fibrinogen, as in Fig. 11 . No preferential release of A, relative to AP, occurred with the defective fibrinogen itself, as demonstrated by the fact that the proportion of A to AP was near 1: 1, just as it was after prolonged incubation (Fig. 10, upper patterns) No consistent differences from normal were evident in the rate of release of fibrinopeptide B from the patient's fibrinogen (Fig. 11) . Two forms of fibrinopep- tide B occurred in both the normal and the patient's fibrinogen, a major component that was labeled B in Fig. 10 , and a minor one labeled B'. The two were identified as being related because neither contained terminal amino groups and were accordingly presumed (27) to contain the pyroglutamic end group of fibrinopeptide B. The fast anodic migration of B, relative to B', has been suggested, but not as yet proven to be due to a deficit of amide ammonia (28) .
Since the release of fibrinopeptide A is essential to clotting (23, 29, 30) , the slow release of the A fibrinopeptides provided a partial explanation for the slow rate of clot formation by the patient's fibrinogen (Fig. 11) .
This, however, did not comprise the only abnormality affecting coagulability. The incomplete yield of fibrin, despite ultimate release of fibrinopeptides in amounts equivalent to normal, appeared due to the poor coagulability of the defective component of the patient's fibrinogen. As already noted, no clot formation was observed when the chromatographically separated defective component was treated by itself with thrombin in 0.3 M NaCl at pH 7.4. As shown by the data of Fig. 11 (4, 6) ; and abnormal clot stabilization has been described in one (10) .
The present studies have demonstrated that the rate of clotting of our patient's plasma or purified fibrinogen by thrombin was abnormal in all of the test systems employed, especially in the presence of low concentrations of thrombin. Development of turbidity, after addition of thrombin to fibrinogen, reflects primarily lateral aggregation of fibrin strands which increases at low pH and ionic strength (31) . The rate of development of turbidity, after addition of thrombin to fibrinogen Baltimore, was delayed. In the presence of low concentrations of thrombin, a prolonged lag period was observed before turbidity increased. (Fig. 1) (3, 14) and its delayed elution from anion exchange columns (26) Morphologic studies of fibrin by light and electron microscopy revealed that the structure of fibrin formed by the patient's fibrinogen after addition of thrombin alone at pH 7.4, was irregular and single fibrin strands appeared less continuous, relatively thin and more transparent than normal fibrin strands. The appearance of fibrin formed by addition of thrombin and calcium chloride to the patient's plasma resembled normal in light microscopy. Slight, and as yet unexplained, differences were still suggested by electron microscopy when clotting occurred in the presence of calcium or at pH 6.4 instead of pH 7.4.
The relationship of these in vitro observations of the functional properties of fibrinogen Baltimore to some of the clinical symptoms, particularly thrombosis, observed in our patient remains unknown. Procedures for the preparation of purified fibrinogen for in vitro studies usually involve removal of cold-insoluble fibrinogen or other forms of altered fibrinogen, which (23, 24) may have biologic activity. Even though the defective component of the patient's fibrinogen appeared virtually incoagulable under simulated physiologic conditions, the possibility exists that thrombic derivatives of the fibrinogen might still form cryoprecipitates analogous to cryoprofibrin (24) . indicates that the high content of phosphate in the patient's fibrinogen is not responsible for its defective coagulation. Yet, the converse possibility has to be considered, namely, that the defective qualities of the fibrinogen were, in part, responsible for its phosphate content. Perhaps, the defective fibrinogen was unable to undergo dephosphorylation as well as normal. Current studies in one of our laboratories 6 indicate that normal fibrinogen can be chromatographically separated into AP-rich and AP-poor species. Such separability will provide a means of assessing phosphorylation and dephosphorylation.
